Literature DB >> 2981640

Kinetics of activation antigen expression by in vitro-stimulated human T lymphocytes.

W Holter, O Majdic, K Liszka, H Stockinger, W Knapp.   

Abstract

In this study a panel of monoclonal antibodies was used to investigate the kinetics of the appearance of activation-linked surface determinants as well as cytoplasmic and nuclear determinants in human T cells following lectin stimulation. Well known activation markers, such as Ia/DR, transferrin receptor, IL-2 receptor, T10, and gp24, were compared and investigated together with the T13 structure, recently found in this laboratory. T13, not demonstrable on resting T cells, could be seen within 24 hr after lectin stimulation. Kinetics of the appearance were similar to IL-2 receptor and transferrin receptor expression. Ia/DR synthesis was investigated separately for each polypeptide and the cytoplasmic invariant gamma-chain expression could be demonstrated for the first time with a gamma-chain-specific monoclonal antibody VIC-Y1. Moreover, gamma-chain synthesis seems to precede alpha- and beta-chain occurrence in human T cells. In addition, data from quantitative studies on antigenic densities are presented.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2981640     DOI: 10.1016/0008-8749(85)90197-2

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  13 in total

1.  Flow cytometric analysis of the stimulatory response of T cell subsets from normal and HIV-1+ individuals to various mitogenic stimuli in vitro.

Authors:  E Medina; N Borthwick; M A Johnson; S Miller; M Bofill
Journal:  Clin Exp Immunol       Date:  1994-08       Impact factor: 4.330

2.  Analysis of T cell activation with a non-mitogenic anti CD3 antibody and the phorbol ester TPA.

Authors:  W Holter; O Majdic; H Stockinger; W Knapp
Journal:  Clin Exp Immunol       Date:  1985-12       Impact factor: 4.330

3.  CD147 monoclonal antibodies induce homotypic cell aggregation of monocytic cell line U937 via LFA-1/ICAM-1 pathway.

Authors:  W Kasinrerk; N Tokrasinwit; P Phunpae
Journal:  Immunology       Date:  1999-02       Impact factor: 7.397

4.  Nonradioactive techniques for measurement of in vitro T-cell proliferation: alternatives to the [(3)H]thymidine incorporation assay.

Authors:  T Messele; M T Roos; D Hamann; M Koot; A L Fontanet; F Miedema; P T Schellekens; T F Rinke de Wit
Journal:  Clin Diagn Lab Immunol       Date:  2000-07

5.  Interleukin-2-induced lymphoproliferative responses.

Authors:  A Winkelstein; L D Weaver; N Salva; L L Machen
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

6.  Cross-reactivity between human hemopoietic cells and brain tumors as defined by monoclonal antibodies.

Authors:  H Budka; O Majdic; W Knapp
Journal:  J Neurooncol       Date:  1985       Impact factor: 4.130

7.  Shared antigenic determinants between human hemopoietic cells and nervous tissues and tumors.

Authors:  H Budka; O Majdic
Journal:  Acta Neuropathol       Date:  1985       Impact factor: 17.088

8.  Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers.

Authors:  X S He; B Rehermann; F X López-Labrador; J Boisvert; R Cheung; J Mumm; H Wedemeyer; M Berenguer; T L Wright; M M Davis; H B Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

9.  Up-regulated expression of Fas antigen (CD95) by peripheral naive and memory T cell subsets in patients with systemic lupus erythematosus (SLE): a possible mechanism for lymphopenia.

Authors:  Y Amasaki; S Kobayashi; T Takeda; N Ogura; S Jodo; T Nakabayashi; A Tsutsumi; A Fujisaku; T Koike
Journal:  Clin Exp Immunol       Date:  1995-02       Impact factor: 4.330

10.  Identification of activated T cells and the suppressor/inducer subset in patients suffering from severe aplastic anemia.

Authors:  U Köller; W Hinterberger; L Gschwandtler; R Grümayer; O Majdic; W Knapp
Journal:  Blut       Date:  1989-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.